The UK and US have announced a major bilateral deal that will preserve no levies on British medicine exports going into the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has agreed to raise funding on drugs through the NHS. This move guarantees that tariffs on these crucial goods will remain at nothing for a timeframe of 36 months.
This agreement comes after earlier threats to significantly raise import taxes on patented drug products, with increases discussed reaching double the cost.
"This deal with the UK reinforces the international landscape for innovative medicines and establishes much-needed fairness to transatlantic medicine commerce," a statement noted.
Economic Importance
Drugs represent one of the Britain's biggest exports to the US, which is by far the primary buyer for leading companies like GSK and AstraZeneca.
Statistics indicate that in the year to the end of last September, the UK sold drugs worth £11.1bn to the US. This figure represented nearly one-fifth of British export trade in that span.
"This deal safeguards jobs, increases funding and paves the way for the UK to become a worldwide center for life sciences," a government official remarked.
Detailed British Pledges
The deal involves several notable changes from the United Kingdom:
- Price Threshold Increase: The UK will increase the cost ceiling at which it considers new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a target to increase total health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The amount drug companies must refund to the NHS to stay within budget will be limited at 15%. In the past, rebates exceeded 20%.
Broader Context
The pact takes place against a protracted tension between the drug companies and the ministers over drug pricing and approval rates.
The disagreement were exacerbated by assertions that American patients were charged several times more for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or cancelled, while substantial expansions have been announced toward American operations.
A senior figure acknowledged that the NHS must increase expenditure on drugs, noting that its spending on drugs had decreased as a share of its resources over the previous ten-year period.
